

Sedasyon Amacıyla Kullanılan İlaçlar Antidotları ve Farmakolojik Özellikleri

Dr. Kutluk Pampal

Sedasyon uygulanacak bir hasta söz konusu olduğunda hasta için en güvenli ve konforlu sedasyon yöntemini ve ajanını belirlemek önemlidir. Hastaya özel sedasyon yöntemi seçilirken; yapılacak işlemin özellikleri, hastanın özellikleri ve hedeflenen sedasyon derinliği gibi faktörlerin yanı sıra kullanılacak ajanların farmakolojik ve farmakodinamik özellikleri, yan etki profilleri de dikkate alınmalıdır. Her ne kadar günümüzde ideal sedasyon ajanına sahip olmasak da **Tablo I-2-1.**'de verilen özellikler üzerinden ideal sedasyon ajanını tanımlamak mümkündür.

Tablo I-2-1. İdeal Sedasyon Ajanının Özellikleri (1,2)

- Etkisi kısa sürede başlamalıdır
- Etki süresi tahmin edilebilmelidir
- Dozu kolay titre edilebilmelidir
- Uygulama sona erdikten sonra etkisi hızla ortadan kalkmalıdır
- Farklı yollardan uygulanabilmelidir
- Terapötik penceresi geniş olmalıdır
- Yan etkileri ve ilaç etkileşimleri minimal olmalıdır
- Ucuz olmalıdır
- Uzun raf ömrüne sahip olmalı ve kolay saklanabilmelidir
- Metabolitleri inaktif olmalıdır

Bu bölümde günümüzde sedasyon amacıyla kullanılan ajanların ve bu ajanların antidotlarının farmakokinetik ve farmakodinamik özellikleri tartışılacaktır. İlaçların sedatif etkilerinin ortaya çıkmasında reseptörler üzerine ne şekilde etki ettikleri önemlidir.

Kaynaklar

1. Berkenbosch JW. Medications Part 1: Sedatives and anxiolytics. In: Procedural Sedation for infants, children and adolescents. Tobiasa JD, Cravero JP., eds., American Academy of Pediatrics Publishing Staff, IL, USA pp 61-90, 2016.
2. Watts J. Drugs in sedation practice. In: Safe sedation for all practitioners. A practical guide. Watts J. CRC Press Taylor & Francis Group, New York, USA, pp 69-86, 2008.
3. Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT. et al. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. *Neuropharmacology*. 2004;47:1146-1156.
4. Orbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. *Br J Pharmacol*. 2006;147(S1):153-162.
5. Zagli G, Viola L. Critical care: The concept. In: Critical care sedation. de Gaudio AR, Romagnoli S., eds., Springer, Switzerland, pp 1-8, 2018.
6. Reisine T. Opiate receptors. *Neuropharmacology*. 1995;34:463-472.
7. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M. et al. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. *Anesthesiology*. 2001; 95:500-508.
8. Lykoudi I, Kottis G, Nikolaou VS, Setaki P, Fassoulaki A. et al. Intra-articular morphine enhances analgesic efficacy of ropivacaine for knee arthroscopy in ambulatory patients. *Orthopedics*. 2011; 34:91.
9. Atcheson R, Lambert DG. Update on opioid receptors. *Br J Anaesth*. 1994; 73:132-134.
10. Rathmell JP, Rosow CE. Intravenous sedatives and hypnotics. In: Stoelting's Handbook of Pharmacology and Physiology in Anesthetic Practice. Stoelting RK, Flood P, Rathmell JP, Shafer S., Wolter Kluwer, PA, USA, pp 119-45, 2015.
11. Insel PA. Adrenergic receptors. Evolving concepts on structure and function. *Am J Hypertens*. 1989; 2:112-118.
12. Glick B. The autonomic nervous system. In: Miller's Anesthesia. Miller RD., ed., Elsevier, Canada, pp 346-86, 2015.
13. Ashton A. Guidelines for the rational use of benzodiazepines: when and what to use. *Drugs*. 1994; 48:25-40.
14. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. *Anesthesiology*. 1990 ;72:926-938.
15. Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. *Eur J Anaesthesiol*. 1988; 2:65-80.
16. Colson JD. The pharmacology of sedation. *Pain Physician*. 2005; 8:297-308.
17. Mohler H, Richards JG. The benzodiazepine receptor: a pharmacological control element of brain function. *Eur J Anaesthesiol*.1988; 2:15-24.
18. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. *Anesthesiology*. 1985; 62:310-324.
19. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. *Br J Anaesth*. 2002; 89:428-437.
20. Spina SP, Ensom MHH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. *Pharmacotherapy*. 2007; 27:389-398.

21. Kaye AD, Gayle J, Kaye AM. Pharmacology principles. In: Modarate and deep sedation in clinical practise. Urman RD, Kaye AD., eds., Cambridge University Press, UK, pp 8-32, 2012.
22. Young CC, Prielipp RC. Benzodiazepines in the intensive care unit. *Crit Care Clin*, 17:843-62, 2001
23. Veselis RA, Reinsel RA, Beattie BJ, Mawlawi OR, Feshchenko. VA et al. Midazolam changes regional cerebral blood flow in discrete brain regions: an H215O positron tomography study. *Anesthesiology*. 1997; 87:1106-1117.
24. Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA et al. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. *Anesthesiology*. 1990; 73:826-30.
25. Skaar D, Weinert C. Sedatives and hypnotics. In: The textbook of critical care, Vincent J, Abraham E, Moore F., eds., Philadelphia, pp 1366–73, 2011.
26. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. *CNS Drugs*. 2001; 15:469-494.
27. Braunstein MC. Apnea with maintenance of consciousness following intravenous diazepam. *Anesth Analg*. 1979; 58:52-53.
28. James K, Briggs S, Lewis R, Mike C. Intrduction to specialist Therapeutics. In: Pharmacology and Pharmacokinetics. Tomlin M., eds., Springer, London, p 59, 2010.
29. Barr J, Zomorodi K, Bertaccini E, Shafer SL, Geller E. A double-blind, randomized comparison of IV lorazepam vs. midazolam for sedation of ICU patients via a pharmacologic model. *Anesthesiology*. 2001; 95:286-291.
30. Hunkeler W, Mohler H, Pieri L, et al. Selective antagonists of benzodiazepines. *Nature*. 1981; 290:514-516.
31. Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. *Br J Clin Pharmacol*. 2016; 81:428-436.
32. Vuyk J, Sitsen E, Reekers M. Intravenous anesthetics. In: Miller's Anesthesia. Miller RD., ed., Elsevier, Canada, pp 821-63, 2015.
33. Brogden RN, Goa KL. Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. *Drugs*. 1991; 42:1061-1089.
34. Cummings K, Naguib MA. Opioid agonists and antagonists In: Stoelting's Handbook of Pharmacology and Physiology in Anesthetic Practice. Stoelting RK, Flood P, Rathmell JP, Shafer S., Wolter Kluwer, PA, USA, pp 157-82, 2015.
35. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. *Anesthesiology*. 1991; 74:53-63.
36. Stein C. The control of pain in peripheral tissue by opioids. *N Engl J Med*. 1995; 332:1685-1690.
37. Roerig DL, Kotrly KJ, Vucins EJ, Ahlf SB, Dawson CA, et al. First pass uptake of fentanyl, meperidine, and morphine in the human lung. *Anesthesiology*. 1987; 67:466-472.
38. Vaughan CW, Connor M. In search of a role for the morphine metabolite morphine-3-glucuronide. *Anesth Analg*. 2003; 97:311-312.
39. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. *J Pharmacol Exp Ther*. 1989; 251:477-483.
40. Peck TE, Hill SA. Core drugs in anaesthetic practise. In: Pharmacology for Anaesthesia and Intensive care. Peck TE, Hill SA., eds., Cambridge university press, UK, pp 93-186, 2014.

41. Stone PA, Macintyre PE, Jarvis DA. Norpethidine toxicity and patient controlled analgesia. *Br J Anaesth.* 1993; 71:738-740.
42. Tissot TA. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. *Anesthesiology.* 2003; 98:1511-1512.
43. Barbani F, Angeli E, de Gaudio AR. Intravenous sedatives and Analgesics In: critical care sedation. de Gaudio AR, Romagnoli S., eds., Springer, Switzerland, p 69-102, 2018.
44. Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. *Anesthesiology.* 1982; 56:93-96.
45. Miller DR, Martineau RJ, O'Brien H, Hull KA, Oliveras L. et al. Effects of alfentanil on the hemodynamic and catecholamine response to tracheal intubation. *Anesth Analg.* 1993;76:1040-1046.
46. Fukuda K. Opioids In: In: Miller's Anesthesia. Miller RD., ed., Elsevier, Canada, pp 346-86, 2015.
47. Burkle H, Dunbar S, Van Aken H. Remifentanyl: a novel, short-acting, mu-opioid. *Anesth Analg.* 1996; 83:646-651.
48. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I. et al. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. *Acad Emerg Med.* 1998; 5:293-299.
49. Rzasa Lynn R, Galinkin J. Naloxone dosage for opioid reversal: current evidence and clinical implications. *Therapeutic Advances in Drug Safety.* 2018; 9:63-88.
50. Boyer EW. Management of opioid analgesic overdose. *N Engl J Med.* 2012; 367:146-155.
51. Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofol-lidocaine mixture. *Anesth Analg.* 2003; 97:1646-1651.
52. Bradley AED, Tober KES, Brown RE. Use of propofol in patients with food allergies. *Anaesthesia.* 2008; 63:439.
53. Dewachter P, Mouton-Faivre C, Castells MC, Hepner DL. Anesthesia in the patient with multiple drug allergies: are all allergies the same? *Curr Opin Anaesthesiol.* 2011; 24:320-325.
54. Murphy A, Campbell DE, Baines D, Mehr S. Allergic reactions to propofol in egg-allergic children. *Anesth Analg.* 2011; 113:140-144.
55. Chidambaran V, Costandi A, D'Mello A. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs.* 2015; 29:543-563.
56. Feng AY, Kaye AD, Kaye RJ, Belani K, Urman RD. Novel propofol derivatives and implications for anesthesia practice. *Journal of Anaesthesiology, Clinical Pharmacology.* 2017; 33:9-15.
57. Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, et al. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. *Clinical Pharmacology & Therapeutics.* 2004; 75:324-330.
58. Takizawa D, Hiraoka H, Goto F, Yamamoto K, Horiuchi R. Human kidneys play an important role in the elimination of propofol. *Anesthesiology.* 2005; 102:327-330.
59. Bouchard N, Nelson L. Opioids. In: Vincent J, Abraham E, Moore F., eds., *The textbook of critical care.* Philadelphia, Elsevier Saunders, pp. 1354-61, 2011.
60. Bryson HM, Fulton BR, Faulds D. Propofol: an update of its use in anaesthesia and conscious sedation. *Drugs.* 1995; 50:513-559.

61. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. *Crit Care Med.* 2002; 30:119-141.
62. Fassoulaki A, Theodoraki K, Melemini A. Pharmacology of sedation agents and reversal agents. *Digestion.* 2010; 82:80-83.
63. Tomatir E, Atalay H, Gurses E, Erbay H, Bozkurt P. Effects of low dose ketamine before induction on propofol anesthesia for pediatric magnetic resonance imaging. *Paediatr Anaesth.* 2004; 14:845-850.
64. Pinaud M, Leausque JN, Chetanneau A, Fauchoux N, Ménégalli D. et al. Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma. *Anesthesiology.* 1990; 73:404-409.
65. Vandesteene A, Trempont V, Engelman E, Deloof T, Focroul M. et al. Effect of propofol on cerebral blood flow and metabolism in man. *Anaesthesia.* 1988; 43:42-43.
66. Keidan I, Perel A, Shabtai EL, Pfeffer RM. Children undergoing repeated exposures for radiation therapy do not develop tolerance to propofol. *Anesthesiology.* 2004; 100:251-254.
67. Sharpe MD, Dobkowski WB, Murkin JM, Klein G, Yee R.. Propofol has no direct effect on sinoatrial node function or on normal atrioventricular and accessory pathway conduction in Wolff-Parkinson-White syndrome during alfentanil/midazolam anesthesia. *Anesthesiology.* 1995; 82:888-895.
68. Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, et al. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. *Anesth Analg.* 2000; 90:25-27.
69. Goodman NW, Black AM, Carter JA. Some ventilatory effects of propofol as sole anesthetic agent. *Br J Anaesth.* 1987; 59:1497-1503.
70. Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, et al. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. *Anesthesiology.* 2004; 101:626-639.
71. Candiotti KA, Gan TJ, Young C, Bekker A, Sum-Ping ST, et al. A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. *Anesth Analg.* 2011; 113:550-556.
72. Lamperti M. Adult procedural sedation: an update. *Curr Opin Anaesthesiol.* 2015; 28:662-667.
73. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. *Clin Pharmacokinet.* 2016; 55:1059-1077.
74. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. *Anesth Analg.* 1998; 87:1186-1193.
75. White PF, Ham J, Way WL, Trevor AJ. Pharmacology of ketamine isomers in surgical patients. *Anesthesiology.* 1980; 52:231-239.
76. Leder MS, Spencer SP, Tobias JD, Stoner MJ. Medications Part 2: ketamin, nitrous oxide and opioids In: *Procedural Sedation for infants, children and adolescents.* Tobiasa JD, Cravero JP eds., American Academy of Pediatrics Publishing Staff, IL, USA pp 91-114, 2016.
77. Sih K, Campbell SG, Tallon JM, Magee K, Zed PJ. Ketamine in adult emergency medicine: controversies and recent advances. *Ann Pharmacother.* 2011; 45:1525-1534.

78. Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. *Neurocrit Care*. 2014; 21:163-173.
79. Hans P, Dewandre PY, Brichant JF, Bonhomme V. Comparative effects of ketamine on Bispectral Index and spectral entropy of the electroencephalogram under sevoflurane anaesthesia. *Br J Anaesth*. 2005; 94:336-340.
80. Butterworth JF, Mackey DC, Wasnick JD. Analgesic Agents. In: *Clinical Anesthesiology*. Butterworth JF, Mackey DC, Wasnick JD., eds., McGraw Hill, USA, pp 175-88, 2013.
81. Arpacı AH, Koç A, Eğritaş Ö, Tosun C, Işık B. Emergence agitation or excited delirium? *GMJ*. 2017; 28:150-151.
82. Tadler S., Brian M. Emerging evidence for antidepressant actions of anesthetic agents. *Curr Opin Anaesthesiol*. 2018; In pres.
83. Butterworth JF, Mackey DC, Wasnick JD. Adrenergic agonists and antagonists. In: *Clinical Anesthesiology*. Butterworth JF, Mackey DC, Wasnick JD., eds., McGraw Hill, USA, pp 239-53, 2013.
84. Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of Dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. *Anaesthesia*. 1999; 54:1136-1142.
85. Khan ZP, Ferguson CN, Jones RM. α_2 - and imidazoline-receptor agonists: Their pharmacology and therapeutic role. *Anaesthesia*. 1999; 54: 146-165.
86. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. *Clinical Pharmacokinetics*. 2017; 56:893-913.
87. Brummett CM, Padda AK, Amodeo FS, Welch KB, Lydic R. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. *Anaesthesiology*. 2009; 11:1111-1119.
88. Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. *Br J Clin Pharmacol*. 2003; 56:691-693.
89. Murthy TVSP, Singh R. Alpha 2 adrenoceptor agonist- Dexmedetomidine role in anaesthesia and intensive care: A clinical review. *Journal of Anaesthesiology Clinical Pharmacology*. 2009; 25:267-272.
90. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. *Anaesthesiology*. 1992; 77:1134-1142.
91. Hsu Y-W, Cortinez LI, Robertson KM, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanyl in healthy volunteers. *Anesthesiology*. 2004; 101:1066-1076.
92. Devasya A, Sarpangala M. Dexmedetomidine: A Review of a Newer Sedative in Dentistry. *J Clin Pediatr Dent*. 2015; 39:401-409.
93. Forman SA. Clinical and Molecular Pharmacology of Etomidate. *Anesthesiology*. 2011; 114:695-707.
94. Craido A, Maseda J, Navarro E, Avello F. Induction of anaesthesia with etomidate: haemodynamic study of 36 patients. *Br J Anaesth*. 1980; 52:803-809.
95. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. *N Engl J Med*. 1984; 310:1415-1421.
96. Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV. et al. Adrenal function in sepsis: The retrospective Corticus cohort study. *Crit Care Med*. 2007; 35:1012-1018.

97. Roberts I, Sydenham E. Barbiturates for acute traumatic brain injury. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No: CD000033.
98. Marseglia L, D'Angelo G, Manti S, Aversa S, Arrigo T et al. Analgesic, Anxiolytic and Anaesthetic Effects of Melatonin: New Potential Uses in Pediatrics. Haenen GRMM, ed. *International Journal of Molecular Sciences*. 2015; 16:1209-1220.
99. Borazan H, Tuncer S, Yalcin N, Erol A, Otelcioglu S. Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial. *J Anesth*. 2010; 24:155-160.
100. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. *Cochrane Database Syst Rev*. 2002;(2):CD001520.
101. Hardeland, R. Poeggeler, B. Melatonin beyond its classical functions. *Open Physiol J*. 2008;1:1-23.
102. Naguib M, Gottumukkala V, Goldstein PA. Melatonin and anesthesia: a clinical perspective. *J Pineal Res*. 2007; 42:12-21.
103. Isik B, Baygin O, Bodur H. Premedication with melatonin vs. midazolam in anxious children. *Paediatr. Anaesth*. 2008; 18:635-641.
104. Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H. et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. *BMC Pharmacol Toxicol*. 2016; 17:8.
105. Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. *Indian Journal of Anaesthesia*. 2013; 57:137-144.
106. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. *J Pineal Res*. 2011; 51:270-277.
107. Malamed SF. Oral Sedation In: *Sedation: A clinical guide to patient management*. Malamed SF., ed., Mosby, China pp 95-118, 2010.
108. Coté CJ, Karl HW, Notterman DA, Weinberg JA, McCloskey C. Adverse sedation events in pediatrics: analysis of medications used for sedation. *Pediatrics*. 2000; 106:633-644.